T Cell Immunity Overview

Principles

Definition

T cell immunity is a fundamental component of the adaptive immune system, mediated by T lymphocytes, which recognizes and responds to specific antigens presented on infected, cancerous, or foreign cells. This academic concept and research field investigates the intricate processes of T cell development, activation, differentiation into various functional subsets (e.g., cytotoxic, helper, regulatory), antigen recognition via the T cell receptor, and the diverse cellular and molecular mechanisms they employ to eliminate pathogens, control abnormal cells, regulate immune responses, and establish immunological memory, highlighting its critical role in host defense, autoimmunity, and cancer immunotherapy.

Ontological type

T cell subsets

TCR recognition

T cell development

Key developments

Key Figures

T cell identity and recognition era

Robert L. Coffman [1] is a central figure in this era with affiliations at Stanford University [3] and The University of Texas Southwestern Medical Center [4]. His key contribution in this era includes the 1986 Coffman paper on two types of murine helper T cells [7], which defined helper T cell heterogeneity by lymphokine activities and secreted proteins and anchored later receptor-based frameworks. Ellis L. Reinherz [2] is a leading figure associated with Harvard University [5] and Boston University [6] during this era. His contributions include the Separation of functional subsets of human T cells by a monoclonal antibody [8], the Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor [9], and A Monoclonal Antibody with Selective Reactivity with Functionally Mature Human Thymocytes and All Peripheral Human T Cells [10], each advancing the receptor-based understanding of T cell identity and antigen recognition.

Costimulation and APC control era

Antonio Lanzavecchia [1] is a leading figure in T cell biology during the costimulation and APC control era, with research affiliations at the Institute of Cancer Research [3] and the University of Pennsylvania [4]. He helped define key functional subsets of memory T lymphocytes and the role of APC licensing in shaping outcomes, exemplified by Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [6] and by Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation [7], underscoring why costimulation and APC-derived signals were pivotal for shaping immunity in this era. Federica Sallusto [2] is a pivotal figure associated with the University of Pennsylvania [4] and with Umeå University [5] in this era. Her work helped map memory T cell heterogeneity and lineage relationships, as reflected in Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [6] and in Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells [8], illustrating how memory programs underpinned polarization and tissue tropism in costimulation-driven immunity.

Therapeutic modulation and repertoires era

Carl H. June [1], a foundational figure in T cell immunotherapy, has worked across institutions such as Harvard University [3] and the University of Pennsylvania [4] during the 2010-2024 era. His key contributions include the Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia [6] (2011) and Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia [7] (2013), which demonstrated that engineered receptors can redirect T cell specificity and durability, catalyzing the era’s shift toward repertoire-guided cancer immunotherapy. Bruce L. Levine [2] is likewise associated with the University of Pennsylvania [4] and University of Maryland, Baltimore [5] during this era. His contributions, as reflected in the same 2011 [6] and 2013 [7] papers, helped establish scalable manufacturing, safety, and durability profiles for adoptive T cell therapies, underpinning the era’s emphasis on repertoire-level control of antigen-specific clones.